Arylindenopyrimidines and their use as adenosine A2a receptor antagonists

Abstract

This invention relates to novel arylindenopyrimidines A, B, and C, and their therapeutic and prophylactic uses. Disorders treated and / or prevented using these compounds include Parkinson's Disease.Formula (I).

Description

Related patent application cross-reference This patent application claims priority to US Provisional Patent Application Serial No. 60 / 982,456, filed October 25, 2007. The entire disclosures of the aforementioned related US patent applications are hereby incorporated by reference herein for all purposes. technical field The present invention relates to novel aryl indenopyrimidines and their therapeutic and prophylactic uses. Disorders that can be treated and / or prevented with these compounds include neurodegenerative disorders and movement disorders that are ameliorated by antagonism of the adenosine A2a receptor. The present patent application relates to a subset of the pending compound species disclosed in patent applications US 20040127510(A1) and WO2005 / 042500A1. Background technique Adenosine A2a Receptor Adenosine is a purine nucleotide produced by all metabolically active cells in the body. Adenosine exerts its effects through four cell surface receptor subtypes ...

AI Technical Summary

Problems solved by technology

Furthermore, it has been found that A2a knockout mice whose A2a function is genetically blocked are less sensitive to motor impairment and neurochemical changes when they are exposed to the neurotoxin MPTP (Chen, J.F.; Xu, K.; I Petzer, J.P. ; Steal, R.; Xu, Y.H.; Beilstein, M.; Sonsalla, P.K.; Castagnoli, K.; Castagnoli, N., Jr.; Schwarsschild, M.A. Journal of Neuroscience, 2001, 121, RC143)

Images